UnknownPhase 4

Ranibizumab Versus Aflibercept for CRVO in Young Patients.

Egypt40 participantsStarted 2021-02-01

Plain-language summary

this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in treatment of macular edema resulting from non ischemic central retinal vein occlusion in patients younger than 5o years old

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. diabetic retinopathy, intraocular inflammation, age related macular degeneration, patients with solar or radiation retinopathy,
✕. patients with ischemic type CRVO and patients who had recent intraocular surgery.
✕. patients who had previous intravitreal injections, ophthalmic laser surgeries.
✕. patients with dense cataracts whom fundus was difficult to scan.
✕. Patients who were lost to follow up visits were also excluded

What they're measuring

Best corrected visual acuity BCVA

Timeframe: at 12 months post-injection

Trial details

NCT IDNCT05282420

SponsorSouth Valley University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-04-01

View on ClinicalTrials.gov More Non-Ischemic Central Retinal Vein Occlusion With Macular Edema trials